{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-007480","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2024-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.843632+00:00","generated_at":"2026-06-06T18:28:52.239537+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"SAB Biotherapeutics regains Nasdaq minimum bid price compliance after reverse split","bullets":["Received Nasdaq notice on Jan 23, 2024 confirming regained compliance with bid price rule.","Company conducted a 1-for-10 reverse stock split on Jan 5, 2024 to help meet the $1.00 minimum close.","Common shares met $1.00 closing bid for 10 consecutive trading days, ending the deficiency.","Prior non-compliance notice was issued Jan 23, 2023; Nasdaq has now closed the matter."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-007480","json":"https://secwatch.observer/filing/0000950170-24-007480.json","markdown":"https://secwatch.observer/filing/0000950170-24-007480.md","text":"https://secwatch.observer/filing/0000950170-24-007480.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024007480/0000950170-24-007480-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024007480/sabs-20240123.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T18:28:52.239537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}